G Pascale Institute Of National Tumor Foundation

Napoli, Italy

G Pascale Institute Of National Tumor Foundation

Napoli, Italy
SEARCH FILTERS
Time filter
Source Type

Di Trolio R.,G Pascale Institute of National Tumor Foundation | Di Lorenzo G.,University of Naples Federico II | Fumo B.,Ministry of Health | Ascierto P.A.,G Pascale Institute of National Tumor Foundation
Future Oncology | Year: 2015

Cosmic radiation can cause genetic and cytogenetic damage. Certain occupations including airline pilots and cabin crew are acknowledged to have a greater exposure to cosmic radiation. In a systematic search of MEDLINE, performed from 1990 to 2014, we analyzed clinical studies using the keywords: cosmic radiation, cancer, chromosome aberration, pilots and astronauts. Increased incidence of skin cancers among airline cabin crew has been reported in a number of studies and appears to be the most consistent finding. However, as with other cancers, it is unclear whether increased exposure to cosmic radiation is a factor in the increased incidence or whether this can be explained by lifestyle factors. Further research is needed to clarify the risk of cancer in relation to cosmic radiation. © 2015 Future Medicine Ltd.


Di Trolio R.,Instituto Nazionale Tumori Fondazione G Pascale | Simeone E.,Instituto Nazionale Tumori Fondazione G Pascale | Di Lorenzo G.,University of Naples Federico II | Grimaldi A.M.,Instituto Nazionale Tumori Fondazione G Pascale | And 5 more authors.
Anticancer Research | Year: 2012

Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon α-2b (PEG-IFN) (Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.


PubMed | G Pascale Institute of National Tumor Foundation
Type: Journal Article | Journal: Future oncology (London, England) | Year: 2015

Cosmic radiation can cause genetic and cytogenetic damage. Certain occupations including airline pilots and cabin crew are acknowledged to have a greater exposure to cosmic radiation. In a systematic search of MEDLINE, performed from 1990 to 2014, we analyzed clinical studies using the keywords: cosmic radiation, cancer, chromosome aberration, pilots and astronauts. Increased incidence of skin cancers among airline cabin crew has been reported in a number of studies and appears to be the most consistent finding. However, as with other cancers, it is unclear whether increased exposure to cosmic radiation is a factor in the increased incidence or whether this can be explained by lifestyle factors. Further research is needed to clarify the risk of cancer in relation to cosmic radiation.


PubMed | G Pascale Institute of National Tumor Foundation
Type: Journal Article | Journal: Anticancer research | Year: 2012

Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon -2b (PEG-IFN) (Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon -2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.

Loading G Pascale Institute Of National Tumor Foundation collaborators
Loading G Pascale Institute Of National Tumor Foundation collaborators